ZS Pharma Presents Positive Results From HARMONIZE, A Second Phase 3 Clinical Trial Of ZS-9 In Patients With Hyperkalemia

By: via Benzinga
ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.